Access to clinical trials of novel treatments, including immune checkpoint inhibitors and CAR T-cell therapy, could be a game changer for these patients, according to Dr Colm Keane. He is a clinical haematologist at the Princess Alexandra Hospital in Brisbane and a brain lymphoma researcher at the University of Queensland's Frazer Institute.
A Phase I investigator-driven clinical trial, which is ready to recruit its first participant, gives Australian patients with high-risk MDS access to two new oral drugs.
Just 28 days after Graeme Ardern had CAR T-cell therapy, he received the most amazing news - he’d had a complete metabolic response.
Professor David Curtis has focused his research on searching for new ways to treat early T-cell precursor acute lymphoblastic leukaemia (ETP-ALL) which he describes as “a nasty type of leukaemia”.
Ten months after his diagnosis and having failed standard treatment, George Yiannakis is the first of potentially 12 Australians to go on the international MM24 clinical trial for AL amyloidosis.
A clinical trial, due to open in mid-2022, will give young people access to two promising new ALL drugs.
Andrew was the first person in Western Australia to have the life-changing therapy.
In a first-ever Australian-French collaboration, an exciting new clinical trial, due to open before Christmas, will give Australians with relapsed or refractory AL amyloidosis access to a new drug combination.
A new platform trial, a world first, could have transformative implications for people with resistant AML.
